Germany Archives

News and Trends 1 Feb 2015

Phenex sells out its main programme to Gilead

Gilead Sciences announces the acquisition of Phenex Pharmaceuticals’ development program for non-alcoholic steatohepatitis (NASH) and other liver diseases. Gilead Sciences and Phenex Pharmaceuticals announced the signing of a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including non-alcoholic steatohepatitis […]

February 1, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 20 Jan 2015

Will Microalgaes solve the Rare Earth conflict?

The extraction of rare earths is a very expensive process, having dramatic consequences for the planet (degradation, impacts on water quality, etc.). Currently, China controls 95% of the World production of these minerals widely used in the field of new technologies and electronics. The development of new methods of sustainable recycling from waste and environmentally friendly is […]

January 20, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 17 Jan 2015

Qiagen, the new giant in next-gen sequencing tools?

Yet again, a new acquisition in this beginning of 2015. Enzymatics, the Boston-area based Biotech company and leading provider of enzymes for Next-gen sequencing, has been acquired by Qiagen for a non-disclosed amount. The amount must be pretty high since Enzymatics’ enzymes are used in 80% of all NGS reactions and the company counts over 150 employees. […]

January 17, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Dec 2014

Promising Agreement Signed for Regenerative Medicine

Heraeus Medical signed an agreement with Locate Therapeutics to license the intellectual property surrounding the use of TAOS in orthopaedic applications and the inception of the first development program in this field. The agreement gives Heraeus Medical GmbH the rights to the future co-developed orthopaedic products as well as the processes involved in manufacturing the final product. […]

December 10, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 1 Dec 2014

The First Gene Therapy Drug Will Be Sold at Record €1,1M Price

What could you buy with €1,1M euros? A house? Or a single prescription for a new drug… The first gene therapy drug “Glybera” is set to go on sale in Germany with a €1.1 million price tag, a new record for a medicine to treat a rare disease. And this drug from UniQure is not the only one […]

December 1, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 28 Nov 2014

One Billion Strategic Oncology Alliance for the Second Largest Antibody Technology Platform

Oxford BioTherapeutics and Menarini Group have initiated the first-in-human clinical study of OBT357, a novel enhanced antibody for the treatment of acute myeloid leukemia (AML). This is the first of five development programs between the two companies to enter the clinic in a $1 billion strategic oncology alliance. Oxford BioTherapeutics and the Menarini Group established their […]

November 28, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 27 Nov 2014

Curetis Raised Additional €14.5M to Diagnose Severe Infectious Diseases

Curetis AG, a developer of next-level molecular diagnostic solutions, has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM Partners in April 2013. Curetis is a young, dynamic and creative molecular diagnostics company. They are specialized in the diagnosis of severe infectious diseases in hospitalized patients. The company helps to combat […]

November 27, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 23 Nov 2014

Munich: Why is it One of the Best Biotech Cluster in Europe ?

The biotech sector in the Greater Munich area continues to demonstrate significant growth in revenue and staff numbers despite ever-increasing international competition. This continues Munich’s status as one of the pre-eminent locations for this future-oriented industry. This was confirmed by the latest study carried out by the City of Munich, the IHK and BioM based […]

November 23, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 22 Nov 2014

After AstraZeneca Turned Down Pfizer’s Bid, Merck Took the Opportunity

Pharmaceutical giants Merck and Pfizer have agreed a deal to develop and market immunotherapy agents to fight cancer. Now, the last Pfizer’s proposal to AstraZeneca is pending. Merck will get an upfront payment of €682 million from the U.S. drugmaker for sharing rights to develop its experimental immunotherapy drug with Pfizer. It is also eligible […]

November 22, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 13 Nov 2014

BIO-Europe, “The place to be for partnering in Europe”

The title may seem a bit catchy, but that’s what lot of companies told me during my visit at BIO-Europe 2014 in Francfort. Why is it so? Surely because of the high profile of attendees, attracted by the prestigious brand and the leadership of BIO’s events. To open the cession, Anna Chrisman, Group managing Director of […]

November 13, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 30 Oct 2014

Review : Ebola, The True Story

The first outbreaks of Ebola (also known as Ebola haemorrhagic fever) have occurred in isolated villages in central Africa, near tropical forests, but the recent outbreak in West Africa has affected major urban centers as well as rural areas. The Ebola virus disease shows an average fatality rate about 50%. In previous outbreaks, the rate […]

October 30, 2014 - 26 minutesmins - By Cédric Brock

News and Trends 20 Oct 2014

European’s First Personalized Vaccines to Treat Brain Cancer

A novel concept of fully personalized therapeutic cancer vaccines, called Glioma Actively Personalized VAccine Consortium (GAPVAC), has been moved into the clinic. It is the first european approval for such a technology. The project is lead by two german Biotech companies Immatics biotechnologies and BioNTech, and received a €6 million grant from European Union. The German National Authorities has approved the […]

October 20, 2014 - 3 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us